CLINUVEL Vitiligo Communiqué
19 December 2018 As a depigmentation disorder hypomelanosis vitiligo is the most...
Read More
CUV103 Singaporean Phase II vitiligo study results
19 December 2018 SUMMARY Phase II study in vitiligo, a treatment-resistant disease1...
Read More
CLINUVEL Newsletter - December 2018
17 December 2018 As the year draws to a close we look back at...
Read More
Results of Meeting
21 November 2018 In accordance with Listing Rule 3.13.2 and section 251AA...
Read More
Managing Director AGM Presentation
21 November 2018 We have enjoyed the longest bull run in equities...
Read More
Chair's Address to the Annual General Meeting
21 November 2018 The value the market has placed on the Company...
Read More
CLINUVEL Newsletter - November 2018
05 November 2018 The most recent quarterly financial results (1 July-30 September...
Read More
Appendix 4C
Appendix 4C Melbourne, Australia and Leatherhead, UK, 31 October 2018 CLINUVEL PHARMACEUTICALS...
Read More
CLINUVEL expands Singapore laboratory facilities
29 October 2018 CLINUVEL PHARMACEUTICALS LTD today announced that its fully owned...
Read More
Appendix 4G and Corporate Governance Statement
18 October 2018 This statement reports on the main corporate governance practices...
Read More
Notice of Annual General Meeting/Proxy Form
18 October 2018 This Explanatory Memorandum has been prepared for the Shareholders...
Read More
Appeal Upheld Against NICE Recommendation in England
10 October 2018 CLINUVEL PHARMACEUTICALS LTD today announced that the Appeal Panel...
Read More
Sachs 18th Biotech in Europe Forum Presentation
08 October 2018 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...
Read More
Chair Letter to Shareholders
05 October 2018 This is a thank you to shareholders, investors, patients,...
Read More
Ceasing to be a substantial holder
04 October 2018 This is a notice regarding an individual or entity...
Read More